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a b s t r a c t
Background: Depression is the predominant pole of illness disability in bipolar disorder and, compared 
with acute mania, has less systematic research guiding treatment development. The aim of this review 
is to present the therapeutic options currently available for managing bipolar depression and to 
highlight areas of unmet need and future research.
Methods: Literature search of PubMed, PsycINFO, and Cochrane databases and bibliographies from 
2000 to August 2013 for treatments that have regulatory approval for bipolar depression or early 
controlled preliminary data on efficacy.
Results: Treatment options for bipolar depression have increased over the last decade, most notably with 
regulatory approval for olanzapine/fluoxetine combination, quetiapine, and lurasidone. Conventional 
mood stabilizers lamotrigine and divalproex have meta-analyses suggesting acute antidepressant 
response. Manual-based psychotherapies also appear to be effective in treating bipolar depression. The 
therapeutic utility of unimodal antidepressants, as a class, for the treatment of patients with bipolar 
depression, as a group, remains to be confirmed. There is a substantially unmet need to develop new 
interventions that are efficacious, effective, and have low side effect burden.
Limitations: Additional compounds are currently being developed that may ultimately be applicable to 
the treatment of bipolar depression and early open-trial data encourage further studies, but both of 
these topics are beyond the scope of this review.
Conclusion: Future registrational trials will need to establish initial efficacy, but increasing interest for 
personalized or individualized medicine will encourage further studies on individual predictors or 
biomarkers of response.
© 2014 Elsevier B.V. All rights reserved.
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1. Introduction
The World Health Organization has ranked bipolar disorder 
or manic-depressive illness among the leading causes of 
disability globally, irrespective of gross national income (World 
Health Organization, 2008). The morbidity associated with 
bipolar dis order is increasingly recognized as not the result 
of mania, about which arguably there has been substantial 
progress in identifying the underlying neurobiology of the 
disease state (Frye et al., 2007b; Strakowski et al., 2012), but 
of depression, treatment-resistant depression, suicidality, and 
a wide range of medical comorbid disorders (Goodwin and 
Jamison, 2007). Episodes of bipolar depression, compared 
with acute mania, are longer, more frequent, and more 
likely associated with suicidality and work-related disability 
(Altshuler et al., 2002; Baldessarini et al., 2012; Calabrese 
et al., 2004; Judd et al., 2002; Kessler et al., 2006; Solomon 
et al., 2010). Despite these high social and public healthcare 
costs demarcating depression as the predominant pole of 
illness burden, depression treatment development has lagged 
substantially compared with both antimanic and maintenance 
pharmacotherapies.
There are 10 drugs approved by the US Food and Drug 
Administration (FDA) for acute mania (lithium, anticonvulsants 
divalproex sodium [delayed and extended release] and 
carba mazepine extended release, typical antipsychotic 
chlorpromazine, and atypical antipsychotics aripiprazole, 
asenapine, olanzapine, quetiapine [immediate and extended 
release], risperidone, and ziprasidone) and 7 drugs approved 
for maintenance treatment (lithium, lamotrigine, aripiprazole, 
olanzapine, quetiapine [imme diate and extended release] 
adjunctive therapy, risperidone long-acting intramuscular 
injection, and ziprasidone adjunctive therapy) (Frye, 2011). Over 
the past decade, however, there have been only 3 treatments 
approved by the FDA for bipolar depression: olanzapine-
fluoxetine (2003), quetiapine [immediate and extended release] 
monotherapy (2006 and 2008), and lurasidone monotherapy 
and adjunctive therapy (2013). Some of the delay in treatment 
development for the depressive phase of bipolar disorder may 
be related to extensive use of unimodal antidepressants and 
psychotherapies in the absence of systematic evaluation of 
bipolar depression. With the exception of fluoxetine, all current 
regulatory-approved antidepressants have received their 
indication in major depressive disorder following trials that 
directly excluded patients with a history of mania (bipolar I) or 
hypomania (bipolar II). This approach has minimized the available 
evidence base that could otherwise inform the clinician on how 
best to utilize these treatments in bipolar disorder. In fact, based 
on the meta-analysis by Sidor and MacQueen (2011; 2012), the 
therapeutic utility of antidepressants for the depressed phase 
of the illness remains to be confirmed. This article reviews the 
current landscape of treatment options for bipolar depression, 
emphasizing points of unmet need and strategic areas for 
subsequent research and treatment development.
2. Methods
We searched PubMed, PsycINFO, and Cochrane databases 
and bibliographies from 2000 to August 2013 for English-
language articles using the following terms: bipolar disorder, 
manic-depressive illness, depression, and treatment. Clinical 
trials registered on ClinicalTrials.gov or trials with a randomized 
placebo-controlled design were considered in this review. The 
search results were reviewed for studies related to currently 
approved treatments or compounds under clinical investigation 
for the treatment of bipolar depression.
3. Results
3.1. Approved treatments
Of the 3 approved treatments for bipolar depression, 
quetiapine has the largest evidence base, encompassing more 
than 2500 bipolar  I and II depressed subjects who participated 
in four 8-week, placebo-controlled trials (Calabrese et al., 2005; 
McElroy et al., 2010; Thase et al., 2006; Young et al., 2010). 
Quetiapine, both 300- and 600-mg doses, resulted in a greater 
baseline-to-endpoint decrease in the Montgomery–Åsberg 
Depression Rating Scale (MADRS) score, higher rate of response 
(≥50% symptom reduction), and higher rate of remission (MADRS 
score ≤12) compared with placebo. Two of the trials included 
lithium (Young et al., 2010) or paroxetine (McElroy et al., 2010) as 
active comparators and quetiapine (300 and 600 mg daily) again 
resulted in a greater baseline-to-endpoint decrease in MADRS 
score and higher rates of response. In the paroxetine study, there 
was more than a 3-fold increase in treatment-emergent switch to 
mania with paroxetine (10.7%) compared with quetiapine (3%). 
A meta-analysis summarizing all of these clinical trials reported 
significantly higher rates of response (odds ratio [OR], 2.00; 95% 
confidence interval [CI], 1.27–2.32) and remission (OR, 1.98; 95% 
CI, 1.70–2.30) with quetiapine compared with placebo (Chiesa 
et al., 2012), with additional data supporting core symptoms 
of bipolar depression as having significantly improved with 
quetiapine versus placebo (Suppes et al., 2010).
The Program to Evaluate the Antidepressant Impact of 
Lurasidone (PREVAIL) registrational trials assessed the efficacy of 
lurasidone in bipolar depression. PREVAIL 1 enrolled 348 bipolar 
I depressed lithium- or valproate-treated participants who were 
randomized to adjunctive lurasidone 20 to 120  mg daily versus 
placebo for 6 weeks (Loebel et al., 2014b). Compared with placebo, 
lurasidone was associated with a significant reduction in MADRS 
scores from baseline to endpoint with a corresponding increased 
rate of response (57% vs. 42%) and remission (50% vs. 35%). The 
PREVAIL  2 trial enrolled 505 bipolar I depressed participants 
randomized to 6  weeks of lurasidone monotherapy (20–60  mg 
daily or 80–120  mg daily) or placebo (Loebel et al., 2014a). 
Again, compared with placebo, lurasidone was associated with a 
significant baseline-to-endpoint reduction in the MADRS score, 
with a corresponding increased rate of response (52% vs. 30%) and 
remission (41% vs. 25%).
The first approved treatment for bipolar depression was 
olanzapine/fluoxetine combination (OFC). Its approval was 
based on an exploratory addition of OFC to an 8-week, placebo-
controlled randomized trial comparing olanzapine monotherapy 
(n=370) with placebo (n=377) in participants with bipolar I 
depression (Tohen et al., 2003). Although a different analytic 
approach (i.e., mixed-effect model repeated measure versus last 
observation carried forward) and a very small sample size (n=86, 
or approximately 10% of the study sample), the combination of 
olanzapine (mean daily dose 7.4 mg) plus fluoxetine (mean daily 
dose 39.3  mg) was superior to placebo in baseline to 8-week 
endpoint changes in MADRS score and response (56.1% vs. 30.4%) 
and remission (48.8% vs. 24.5%) rates. Most likely related to 
the antimanic properties of olanzapine, the manic switch rate 
was not significantly different between the combination (6.4%) 
and placebo (6.7%) groups. Although olanzapine monotherapy 
(mean dose 9.7  mg daily) was superior to placebo in improving 
depression, the overall decrease in MADRS score was significantly 
greater with OFC.
The evidence base for olanzapine has increased with a 
6-week, placebo-controlled study evaluating olanzapine mono-
therapy (n=343) for bipolar I depression (Tohen et al., 2012). 
Compared with placebo (n=171), olanzapine was associated with 
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a significantly greater decrease in MADRS score and increased 
rate of response (52.5% vs. 43.3%; p=0.0498) and remission 
(38.5% vs. 29.2%; p=0.038), but not recovery (13.7% vs. 9.4%; 
p=0.156). Concern has been raised as to whether the positive 
evidence base for olanzapine or quetiapine in bipolar depression 
represents a therapeutic benefit (i.e., addressing core symptoms 
of depression) versus a side effect benefit of a sedating, weight-
liable compound promoting sleep and appetite that, as such, 
addresses key non-core symptoms of insomnia and poor appetite/
weight loss. In addition to a quetiapine core symptom analysis 
(Suppes et al., 2010), a recent pooled analysis of olanzapine 
monotherapy studies in acute bipolar depression reported that 
core symptoms of depression (6 items from the MADRS) showed 
greater improvement with olanzapine compared with placebo 
(Tohen et al., 2013).
Although the atypical antipsychotics, as a class, have 
antimanic properties (e.g., 6 agents are approved for acute 
mania), this does not appear to be the case for bipolar 
depression, as the current evidence base for both aripiprazole 
and ziprasidone has negative studies (Sachs et al., 2011; Thase 
et al., 2008). The six-week ziprasidone study that failed to 
show separation from placebo for bipolar depression (Sachs et 
al., 2011) and a recent post hoc analysis of the subject rating 
data (Lombardo et al., 2012) both emphasize the importance of 
data monitoring in the course of a clinical trial. Furthermore, 
the analysis of two 8-week trials of aripiprazole did show 
statistically significant separation from placebo through week 
six, but did not, at the final 8-week end point, show a statistically 
significant difference between drug and placebo (Thase et al., 
2008). Major concerns for quetiapine, lurasidone, olanzapine, 
and OFC focus on risks of weight gain with associated risk 
of diabetes, cardiometabolic factors, and tardive dyskinesia. 
Tardive dyskinesia cannot be estimated from short-term trials, 
though data suggest that the tardive dyskinesia risk is lower 
with second-generation atypical versus first-generation typical 
antipsychotic agents, which have estimates of ~3–5% per year of 
exposure (Kane, 2006). In this issue, Dr. David Kemp reviews the 
clinical management of side effects associated with commonly 
used treatments for bipolar depression.
3.2. Mood stabilizers in the treatment of acute bipolar depression
There is merit to initially treating an episode of bipolar 
depression with monotherapy from the standpoint of minimizing 
pharmacokinetic interactions and maximizing treatment 
adherence. As such, evaluating antimanic and maintenance mood 
stabilizers for their efficacy in bipolar depression may obviate the 
need for augmentation or adjunctive therapy.
Despite lithium’s gold standard status as an active comparator 
in acute mania, it is not FDA-approved for bipolar depression. 
There has been little contemporary systematic research on 
the acute antidepressant response to lithium, and the limited 
recent data available are negative (Bhagwagar and Goodwin, 
2002; Fountoulakis and Vieta, 2008). One exploratory post hoc 
analysis has suggested a differential antidepressant response 
based on serum lithium levels. In a 10-week, placebo-controlled 
comparison study evaluating adjunctive antidepressant therapy, 
lithium-maintained bipolar I depressed participants were 
randomized to paroxetine (n=35, mean daily dose 32.6  mg), 
imipramine (n=39, mean daily dose 166.7 mg), or placebo (n=43) 
stratified by naturalistic maintenance therapeutic (>0.8 mmol/L) 
versus nontherapeutic (≤0.8 mmol/L) lithium level (Nemeroff et 
al., 2001). The primary outcome measures, baseline to endpoint 
change in the Hamilton Rating Scale for Depression (HAM-D) and 
treatment response (HAM-D ≤7 or Clinical Global Impression 
[CGI] global improvement ≤2), were not significantly different 
among the 3 groups, nor was there a difference found among the 
groups in a post hoc analysis of participants with a therapeutic 
lithium level. However, in the group with nontherapeutic 
lithium level, adjunctive selective serotonin reuptake inhibitor 
(SSRI) and tricyclic antidepressant (TCA) treatments were both 
associated with a significant reduction in depressive symptoms 
compared with placebo, indirectly suggesting that for patients 
who can achieve and tolerate a higher serum level of lithium, 
adjunctive treatment may not be necessary, although this 
needs to be confirmed prospectively. Similar findings have 
been observed in depression prophylaxis. In a non-enriched, 
post hoc analysis of bipolar I patients stabilized from a manic/
mixed or depressive episode, time to recurrence of any mood, 
manic, or depressive event was significantly longer in patients 
who achieved a median lithium level between 0.6 and 1.2 mEq/L 
(n=201) versus patients randomized to placebo (n=404) and 
versus patients who achieved a median lithium level <0.6 mEq/L 
(n=137) (Nolen and Weisler, 2013). Although the groups were 
not stratified on the basis of therapeutic level of lithium 
(>0.8 mmol/L), these data emphasize that when tolerable, higher 
dosing of mood stabilization treatment may be associated with 
better mood outcomes, although this also needs to be confirmed 
prospectively.
There is increasing recognition that subtle changes in thyroid 
economy related to lithium may reduce therapeutic effectiveness, 
particularly for depression. Support for this premise comes from 
studies demonstrating that lower mean serum free T4 or increased 
adjusted mean thyroid-stimulating hormone (TSH) levels during 
lithium maintenance treatment were associated with more 
affective episodes (p<0.01), increased depression severity (p<0.01), 
and a higher percentage of participants requiring intervention for 
depression (Frye et al., 1999a; Frye et al., 2009b). This, in turn, 
may relate to thyroid-induced changes on brain function, as 
neuroimaging of medication-free participants with treatment-
resistant mood disorders, primarily rapid-cycling bipolar disorder, 
has demonstrated a significant inverse correlation between 
peripheral TSH levels and cerebral blood flow and cerebral glucose 
metabolism (Marangell et al., 1997b).
Lamotrigine, a drug approved by the FDA for the maintenance 
phase (i.e., delaying manic and depressive recurrence) of bipolar I 
disorder, is not FDA-approved for acute bipolar depression, but a 
meta-analysis (5 studies, 1 positive, 4 negative) and 1 controlled 
LamLit study suggest possible efficacy in acute bipolar depression 
(Geddes et al., 2009; Goodwin et al., 2004; van der Loos et al., 
2009).
The meta-analysis of 5 placebo-controlled trials (n=1072 bipolar 
I and II patients) with variable study duration (7–10 weeks) 
and dosing regimens (fixed dose, 50 mg vs. 200 mg; flexible 
dosing 100–400 mg), reported a modest benefit of lamotrigine 
monotherapy as assessed by a ≥50% decrease in MADRS (relative 
risk [RR]=1.22; 95% CI, 1.06–1.41) or HAM-D (RR=1.27; 95% CI, 
1.09–1.47) scores; a planned subgroup analysis revealed a greater 
treatment effect in patients with severe depression (Geddes et 
al., 2009). Remission rates were not significantly different with 
lamotrigine relative to placebo.
These monotherapy data have been further supported by the 
LamLit study, an 8-week, randomized, placebo-controlled trial 
of 124 lithium-maintained bipolar I/II depressed outpatients, in 
which adjunctive therapy with 200  mg lamotrigine resulted in 
greater improvement in the MADRS score and a higher response 
rate than did adjunctive placebo (51.6% vs. 31.7%) (van der Loos et 
al., 2009).
Finally, divalproex sodium, approved for acute mania, has also 
been studied as monotherapy for bipolar depression. In a meta-
analysis of 4 small, short-term (6–8 week) placebo-controlled 
trials with a total of 142 bipolar I or II patients, divalproex 
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monotherapy resulted in a significant difference in both depression 
symptom scale score reduction (Smith et al., 2010) and rates of 
clinical response (RR=2.1; 95% CI, 1.1–2.43; p=0.02) and remission 
(RR=1.61; 95% CI, 1.12–2.53; p=0.04) (Bond et al., 2010; Smith et al., 
2010). Although divalproex is not FDA-approved for maintenance 
treatment, secondary analyses of maintenance studies suggest 
reduced depressive recurrence with divalproex and less need for 
adjunctive antidepressant therapy (Bowden et al., 2000; Gyulai et 
al., 2003).
3.3. Antidepressants in the treatment of bipolar depression
One of the most controversial topics in mood disorder 
management is the disconnect between the evidence base 
and the clinical use of antidepressants in bipolar disorder 
(Pacchiarotti et al., 2013). Although naturalistic and prescription 
data suggest that the use of antidepressants in bipolar disorder 
is highly prevalent (Baldessarini et al., 2007), the evidence base 
to suggest efficacy is far from robust. Paroxetine is the SSRI most 
rigorously studied in bipolar depression. The cumulative data 
to date for paroxetine suggest less effectiveness in improving 
depression versus quetiapine monotherapy, with a higher 
switch rate to mania/hypomania (McElroy et al., 2010); no 
better results than placebo in reducing depressive symptoms 
in lithium-maintained patients (Nemeroff et al., 2001); and 
no added benefit as adjunct treatment to mood stabilizers 
compared with placebo in measures of durable recovery, defined 
as 8 consecutive weeks of euthymia without switch to mania/
hypomania (Sachs et al., 2007). Moreover, a meta-analysis of 
randomized double-blind trials comparing acute antidepressant 
treatment with either placebo or active comparator likewise 
demonstrated no significant benefit of antidepressant therapy in 
rates of response (n=1145; RR=1.17; 95% CI, 0.88–1.57; p=0.28) or 
remission (n=1146; RR=1.14; 95% CI, 0.90–1.45; p=0.28) (Sidor and 
MacQueen, 2012; Sidor and MacQueen, 2011). Antidepressants 
may result in better outcomes for patients with bipolar II 
depression, as evidenced by the significant benefit of depression 
prophylaxis with fluoxetine in these patients compared with 
lithium or placebo maintenance (Amsterdam and Shults, 2010). 
These data highlight the important need for further steps in 
identifying clinical patterns associated with antidepressant 
treatment response.
A second concern regarding antidepressant use in bipolar 
disorder is safety. Pooled treatment estimates do not suggest 
an increased acute risk of switch from depression to mania/
hypomania (Sidor and MacQueen, 2012; Sidor and MacQueen, 
2011). However, smaller analyses have suggested that venlafaxine 
(Post et al., 2006; Vieta et al., 2002) and TCAs (Peet, 1994) have 
been associated with higher acute switch rates than other 
antidepressant compounds. Furthermore, there is increasing 
recognition that additional clinical and genomic correlates may 
be associated with antidepressant-induced mania (AIM) (Frye 
et al., 2009a; Frye et al., 2014; in press). Five studies reported in 
an earlier meta-analysis (Biernacka et al., 2012), plus additional 
work from Frye et al. (2014), have evaluated genomic variation of 
the SLC6A4 promoter and AIM in adults (total, N=453 AIM+ cases; 
N=725 AIM– controls) (Frye et al., 2014; Ferreira Ade et al., 2009; 
Masoliver et al., 2006; Mundo et al., 2001; Rousseva et al., 2003; 
Serretti et al., 2004). The meta-analysis demonstrated a weak, 
not statistically significant association of the S allele with AIM+ 
(OR, 1.87; 95% CI 0.99–1.85; p=0.059). In order to optimize the 
potential clinical impact of pharmacogenomic research of AIM, 
future studies should include adequate sample size and rigorously 
assessed patient characteristics (e.g., family history, rapid cycling, 




There is an urgent need to develop new trial designs and 
novel treatments for bipolar depression. The delays have been 
multifactorial, and an optimal trial design (i.e, duration, symptom 
scale measurement, outcome and adverse event measurement, 
biomarkers of response) has yet to be determined. This is in 
contrast with the now conventional 3-week, placebo-controlled 
design for acute mania studies, with a 50% reduction in symptom 
severity, as measured by the Young Mania Rating Scale (YMRS), 
as a key outcome measure; this was the template for most of the 
more than 60 studies in a recent meta-analysis (Cipriani et al., 
2011). The trial design for the OFC and quetiapine pivotal trials 
in bipolar depression was an 8-week placebo-controlled study 
with at least a 50% reduction in the MADRS score as the primary 
response outcome measure (Calabrese et al., 2005; McElroy et al., 
2010; Thase et al., 2006; Tohen et al., 2003; Young et al., 2010). 
However, some studies of bipolar depression have used a 6-week 
outcome with positive results (Frye et al., 2007a; Loebel et al., 
2014a; Loebel et al., 2014b), or had the primary outcome measure 
met at 6 weeks but not at the 8-week a priori defined outcome 
endpoint (Thase et al., 2008).
Secondly, there is increasing interest in alternative rating 
scales, such as the Inventory for Depressive Symptoms, which 
includes quantification of atypical (non-melancholic) symptoms 
(Calabrese et al., 2010; Frye et al., 2007a; Post et al., 2006; Rush et 
al., 1986; Rush et al., 1996).
Thirdly, while treatment-emergent or antidepressant-induced 
mania would meet criteria for conventional response and 
remission, there has been debate on how best to quantify this 
event (i.e., adverse event or safety issue vs. lack of overall mood 
response) (Frye et al., 2014; in press). There has been progress 
to more reliably capture this event with instruments such as the 
CGI for Bipolar Disorder–change from preceding phase (Spearing 
et al., 1997), or outcomes such as durable recovery or treatment 
effectiveness response (Sachs et al., 2007).
Finally, there has been little symptom scale development for 
the assessment of mixed symptoms in depression. As “mixed 
features” are recognized as a specifier for bipolar disorder in 
the Diagnostic and Statistical Manual of Mental Disorders, fifth 
edition, and are known to be a risk factor for poor outcome (Judd 
et al., 2012), developing a symptom severity measure has obvious 
clinical research appeal. The YMRS scale was originally developed 
for manic inpatients, and its sensitivity to detect subtle hypomanic/
manic symptoms may be limited. Self-report pilot scales such as 
the modified version of the Hypomania Checklist-32 may have 
merit and warrant further study (Altinbas et al., 2014; Prieto et al., 
2014; in press).
New trial designs should not only standardize trial duration 
and primary outcome measurement scales, but also utilize 
outcome measures that focus not only on response and remission 
but also on cognition, quality of life, functional improvement, 
recovery, and targeted comorbidity patterns (i.e., suicidality, 
addiction, anxiety disorders, obesity, cardiovascular disease), 
which may have long-term prognostic implications. Additionally, 
effective community translation and dissemination of the data 
that provide the clinician with a greater ability to understand the 
practical impact of the study (i.e., effect size, number needed to 
treat [NNT], number needed to harm [NNH], ratio of NNT to NNH) 
would foster substantial progress. In this issue, Dr. Terence Ketter 
and colleagues use NNT and NNH approaches to evaluate the 
safety and efficacy of treatments for bipolar depression.
In addition to the evolution of trial design, novel compounds 
beyond atypical antipsychotics and novel treatment interventions 
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need to be studied. For example, early controlled evaluations or 
biomarker development studies of the glutamatergic compounds 
ketamine (Zarate, Jr. et al., 2012) and riluzole (Brennan et al., 2010; 
Zarate, Jr. et al., 2005), the dopamine D2/D3 receptor partial agonist 
pramipexole (Goldberg et al., 2004; Zarate, Jr. et al., 2004), and 
the dopamine transport inhibitors modafinil (Frye et al., 2007a) 
and armodafinil (Calabrese et al., 2010), clearly warrant further 
evaluation; however, positive results were observed in only one 
(Calabrese et al., 2014) of three (Adler et al., 2014; Frye et al., 
2013) subsequent clinical trials of armodafinil. Early interest in 
inflammatory models of illness progression (Leboyer et al., 2012) 
and feasibility and early controlled studies of N-acetylcysteine 
(Berk et al., 2012) and celecoxib (Nery et al., 2008) warrant further 
study as well. Treatments focused on circadian rhythms such as 
sleep deprivation (Smeraldi et al., 1999; Szuba et al., 1994) and 
thyrotropin-releasing hormone (Frye et al., 1999b; Marangell et 
al., 1997a) may be effective by themselves, but may also be used as 
accelerating paradigms in reducing bipolar depressive symptoms 
faster to, in turn, reduce morbidity and symptom severity 
(Altshuler et al., 2003).
Characterization of illness staging may also help to inform 
treatment options and stratify responses to improve both 
clinical trial design and data interpretation. For example, illness 
progression is associated with structural brain changes, functional 
decline, and an increasing vulnerability to relapse of depressive 
episode and treatment resistance (Dodd et al., 2013). Multiple 
neurobiological mechanisms mediate this neuroprogression, 
including alteration of neurotransmitters, neurotrophic factors, 
inflammatory mediators, insulin dysfunction, oxidative stress, 
mitochondrial dysfunction, and hypothalamic-pituitary-adrenal 
axis dysregulation (Brietzke et al., 2011; Dodd et al., 2013). As the 
field moves forward and appreciation of the effect of integrative 
biological systems on disease progression and corresponding 
treatment response increases, we will be far better placed to 
develop more targeted and individualized treatments for bipolar 
depression (Tye, 2013). Ideally, if multiple measures across these 
intertwined biological systems can be incorporated into study 
design, we will be much better placed to correlate treatment 
response profiles with pathophysiological disease processes. 
This, in turn, will facilitate identification of novel treatments 
or treatment combinations for bipolar depression that can be 
individualized for each patient in accordance with their unique 
biosignature (Phillips and Kupfer, 2013). Last, but not least, this 
type of research must aim to keep pace with recent calls to address 
diagnostic issues from a different, more strictly neurobiological 
(genetic, neural circuit–, and systems-based), approach (Cuthbert 
and Insel, 2013). Clinical research samples can have different 
configurations to assess dimensions such as severity and causation.
4.2. Limitations
Additional compounds are currently being developed that may 
ultimately be applicable to the treatment of bipolar depression, 
and early open-trial data encourage further studies. However, 
both topics are beyond the scope of this review.
5. Conclusions
While the number of treatment options for bipolar depression 
has increased over the last decade, there is a substantial unmet 
need for new interventions that are efficacious and effective, and 
that have a low side effect burden. Future registrational trials will 
need to establish initial efficacy, together with well-characterized 
treatment-response profiles. This strategy will provide the 
necessary foundation on which a personalized medicine approach 
can be established within the field of psychiatry, and encourages 
eventual diagnostic improvements in addition to further pursuit 
and development of individual predictors or biomarkers of 
response.
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